Clarius Group LLC Purchases 21,661 Shares of Pfizer Inc. $PFE

Key Points

• Clarius Group LLC increased its holdings in Pfizer Inc. by 114.0%, acquiring an additional 21,661 shares to bring its total to 40,662 shares valued at $986,000.
• Institutional investors collectively own 68.36% of Pfizer’s stock, with several hedge funds significantly increasing their stakes during the recent quarter.
• Pfizer reported earnings of $0.78 per share for the last quarter, exceeding analyst expectations, with revenue growth of 10.3% year-over-year.

Clarius Group LLC increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 114.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,662 shares of the biopharmaceutical company's stock after acquiring an additional 21,661 shares during the quarter. Clarius Group LLC's holdings in Pfizer were worth $986,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Pacer Advisors Inc. lifted its stake in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after buying an additional 17,957,928 shares in the last quarter. Amundi lifted its stake in Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new position in Pfizer in the first quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. lifted its stake in Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after buying an additional 7,581,030 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PFE. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Saturday, September 27th. UBS Group reaffirmed a "neutral" rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $28.41.

Pfizer Price Performance

Shares of PFE opened at $27.37 on Friday. The company has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company's fifty day simple moving average is $24.67 and its 200 day simple moving average is $24.14. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.